Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Chris Lange | Feb 5, 2016 at 10:40 AM EST

Mapi Pharma Closes in on IPO

Mapi Pharma expects to price more than 3 million shares in the range of $15 to $17 in an initial…

Chris Lange | Feb 5, 2016 at 8:40 AM EST

Quotient Gears Up for Secondary Offering

Quotient led the bulls going into Friday’s trading session on news of a secondary offering.

Jon C. Ogg | Feb 4, 2016 at 2:20 PM EST

Why TherapeuticsMD Could Still Rise Almost 200%

TherapeuticsMD shares were active on Thursday after an analyst report suggested that the stock could have up to almost 200%…

Chris Lange | Feb 4, 2016 at 1:15 PM EST

Credit Suisse Identifies 5 Stocks to Buy Winning From Your Pet’s Health

Credit Suisse made a point to highlight a few animal health companies that stand to outperform the markets in 2016…

Chris Lange | Feb 4, 2016 at 11:05 AM EST

Therapure Biopharma Postpones IPO

Therapure Biopharma has announced that, due to current conditions in capital markets, it would postpone its initial public offering.

Chris Lange | Feb 4, 2016 at 9:55 AM EST

Will Sinovac Go Through With This Buyout?

Sinovac Biotech Ltd. (NASDAQ: SVA) was riding high early Thursday morning, following the offer for a potential buyout, but it…

Chris Lange | Feb 3, 2016 at 11:55 AM EST

BeiGene Explodes Into the Market

BeiGene entered the market with a bang on Wednesday in its initial public offering priced at the high end of…

Chris Lange | Feb 3, 2016 at 11:45 AM EST

Editas Announces Final Pricing for IPO

Editas Medicine will price its nearly 6 million shares at $16 apiece in an initial public offering valued at more…

Chris Lange | Feb 3, 2016 at 8:45 AM EST

Merck Trips Up Over Mixed Earnings

Merck reported mixed fourth-quarter financial results before the markets opened Wednesday.

Chris Lange | Feb 2, 2016 at 4:31 PM EST

Gilead Rises on Solid HCV Sales and Earnings Beat

Gilead Sciences reported better-than-expected fourth-quarter financial results after the markets closed on Tuesday.

Chris Lange | Feb 2, 2016 at 12:55 PM EST

What Expect From Gilead Earnings

Gilead Sciences is set to release its fourth-quarter earnings report after the markets close on Tuesday.

Chris Lange | Feb 2, 2016 at 12:05 PM EST

AveXis Announces Potential Price for IPO

AveXis expects to price more than 4 million shares in the range of $19 to $21 in an initial public…

Paul Ausick | Feb 2, 2016 at 8:05 AM EST

Investors OK With Pfizer Earnings, Not OK With Guidance

Pfizer reported better-than-expected fourth-quarter and full-year 2015 results before markets opened Tuesday morning.

Chris Lange | Feb 1, 2016 at 1:25 PM EST

What to Expect From Pfizer Earnings

Pfizer is scheduled to report its fourth-quarter financial results before the markets open on Tuesday.

Chris Lange | Feb 1, 2016 at 12:15 PM EST

PLx Pharma Gets Closer to IPO Debut

More than 3 million PLx Pharma shares are expected to price in the range of $17 to $19 per share…

1 … 224 225 226 227 228 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Mapi Pharma Closes in on IPO

Quotient Gears Up for Secondary Offering

Why TherapeuticsMD Could Still Rise Almost 200%

Credit Suisse Identifies 5 Stocks to Buy Winning From Your Pet’s Health

Therapure Biopharma Postpones IPO

Will Sinovac Go Through With This Buyout?

BeiGene Explodes Into the Market

Editas Announces Final Pricing for IPO

Merck Trips Up Over Mixed Earnings

Gilead Rises on Solid HCV Sales and Earnings Beat

What Expect From Gilead Earnings

AveXis Announces Potential Price for IPO

Investors OK With Pfizer Earnings, Not OK With Guidance

What to Expect From Pfizer Earnings

PLx Pharma Gets Closer to IPO Debut

Wall Street CIO: The AI Trade is “Technically Unsustainable.” Buy These Two Industries Instead.

Wall Street Strategist: SpaceX Will Force a Major Stock Market Repositioning. Buy These Stocks Instead.

3 Dividend Stocks Built for Retirement to Buy in June

Retired Couple With $1.9 Million Faces $4,800 IRMAA Surprise After Stock Sale

A $900,000 Nest Egg at 65 Only Translates to About $36,000 in Real Annual Spending After Taxes and Inflation

Wall Street CIO: The AI Trade is “Technically Unsustainable.” Buy These Two Industries Instead.

Wall Street Strategist: SpaceX Will Force a Major Stock Market Repositioning. Buy These Stocks Instead.

Health and Healthcare Articles

All Health and Healthcare Articles

Mapi Pharma Closes in on IPO

Quotient Gears Up for Secondary Offering

Why TherapeuticsMD Could Still Rise Almost 200%

Credit Suisse Identifies 5 Stocks to Buy Winning From Your Pet’s Health

Therapure Biopharma Postpones IPO

Will Sinovac Go Through With This Buyout?

BeiGene Explodes Into the Market

Editas Announces Final Pricing for IPO

Merck Trips Up Over Mixed Earnings

Gilead Rises on Solid HCV Sales and Earnings Beat

What Expect From Gilead Earnings

AveXis Announces Potential Price for IPO

Investors OK With Pfizer Earnings, Not OK With Guidance

What to Expect From Pfizer Earnings

PLx Pharma Gets Closer to IPO Debut

Wall Street CIO: The AI Trade is “Technically Unsustainable.” Buy These Two Industries Instead.

Wall Street Strategist: SpaceX Will Force a Major Stock Market Repositioning. Buy These Stocks Instead.

3 Dividend Stocks Built for Retirement to Buy in June

Featured Reads

Retired Couple With $1.9 Million Faces $4,800 IRMAA Surprise After Stock Sale

A $900,000 Nest Egg at 65 Only Translates to About $36,000 in Real Annual Spending After Taxes and Inflation